Which public longevity infrastructure solutions offer best ROI?
The best returns in public longevity infrastructure come from the cheapest measures: tobacco and alcohol taxes (which make money while saving lives), salt and sugar policy, adult vaccination, blood-pressure control, smoking-cessation services and falls-prevention exercise. Cancer screening pays within guideline ages and not outside them; walkable cities and clean air pay slowly on observational evidence; longevity clinics and national longevity institutes have no demonstrated return in healthy years. Prevention is good value but usually not a cash saving, and quoted returns like 14:1 come with heavy caveats.
Return on investment in public longevity infrastructure ranges from negative to better than 30:1 depending on the programme, the perspective and the discount rate, so the ranking below states the evidence for each rather than a single number. Ranked on cost per healthy life-year with the caveats attached: tobacco and alcohol taxation first, because they raise revenue while reducing consumption, deaths and morbidity — the only longevity infrastructure that is cash-positive for a treasury on day one; fiscal and regulatory measures on salt, sugar and trans fats second, cheap to implement with large modelled cardiovascular gains and growing real-world evidence; vaccination delivery for older adults third, with well-established cost-effectiveness for influenza, pneumococcal and shingles vaccines and cost-saving results in some analyses; hypertension detection and control fourth, dominant or highly cost-effective in every serious model because the treatment costs pennies and the strokes it prevents cost thousands; smoking-cessation services fifth, among the most cost-effective clinical interventions ever evaluated; falls-prevention exercise sixth, cost-effective on trial evidence and rarely funded at scale; organised cancer screening seventh, cost-effective for colorectal, cervical and breast within guideline ages and negative outside them; active-travel and clean-air infrastructure eighth, high modelled returns on observational evidence with long payback; and longevity clinics, national longevity institutes and epigenetic-age programmes last, with no demonstrated healthy-year return. The framing caveat from the site's public-longevity section applies to every row: the median prevention ROI of 14.3:1 comes with publication bias and discount rates from 0% to 10%, prevention is cost-effective rather than cost-saving, and lifetime medical costs are highest among the people who live longest.
- Only taxation is cash-positive immediately; everything else is cost-effective at best.
- Hypertension control and vaccination are the highest-return service programmes because the interventions are nearly free.
- Falls-prevention exercise has trial evidence and almost no funding; it is the cheapest unexploited return.
- Screening ROI turns negative outside guideline ages; more is not better.
- Longevity clinics and institutes have no healthy-year return to show; they are not infrastructure ROI.
Public longevity solutions ranked on return per healthy year
Ranked on: evidence for cost per healthy life-year (or QALY) at population scale, from trials, natural experiments and peer-reviewed economic models; whether the measure is cash-positive, cost-saving, cost-effective or unproven; and the size of the population effect.
| # | Option | Verdict | Grade |
|---|---|---|---|
| 1 | Tobacco and alcohol taxation | Cash-positive on day one; deaths and morbidity fall | GRADE AEstablished |
| 2 | Salt, sugar and trans-fat policy | Cheap to implement; large modelled cardiovascular gains | GRADE AEstablished |
| 3 | Adult vaccination delivery | Well-established cost-effectiveness; cost-saving in some analyses | GRADE AEstablished |
| 4 | Hypertension detection and control | Dominant or highly cost-effective in every serious model | GRADE AEstablished |
| 5 | Smoking-cessation services | Among the most cost-effective clinical interventions evaluated | GRADE AEstablished |
| 6 | Falls-prevention exercise programmes | Trial-proven, cost-effective, unfunded | GRADE BPromising |
| 7 | Organised cancer screening within guideline ages | Cost-effective inside the guidelines; negative outside | GRADE BPromising |
| 8 | Active-travel and clean-air infrastructure | High modelled returns; observational evidence; long payback | GRADE BPromising |
| 9 | Longevity clinics, national longevity institutes, epigenetic-age programmes | No demonstrated healthy-year return | GRADE DInsufficient or unsafe |
- 01
Tobacco and alcohol taxation
GRADE AEstablishedCash-positive on day one; deaths and morbidity fallExcise increases raise revenue while reducing consumption, with the largest health gains among the poorest. Minimum unit pricing for alcohol has real-world evidence of reduced deaths. The only longevity infrastructure that pays the treasury immediately rather than eventually; every serious ROI league table puts it first.
- 02
Salt, sugar and trans-fat policy
GRADE AEstablishedCheap to implement; large modelled cardiovascular gainsReformulation targets, trans-fat bans, sugar levies and salt reduction. Implementation costs are small, modelled reductions in cardiovascular events are large, and real-world evidence (trans-fat bans, the UK sugar levy's reformulation effect) is accumulating. Cost-saving in most models.
- 03
Adult vaccination delivery
GRADE AEstablishedWell-established cost-effectiveness; cost-saving in some analysesInfluenza, pneumococcal, shingles and COVID vaccination of older adults, delivered through pharmacies and call-recall. Cost-effective in essentially every evaluation, cost-saving in several; the shingles vaccine's dementia signal, if confirmed, would improve the figure further. The infrastructure cost is uptake.
- 04
Hypertension detection and control
GRADE AEstablishedDominant or highly cost-effective in every serious modelScreening plus generic antihypertensives costing pennies a day, with protocol titration by pharmacists or nurses, against strokes and heart attacks costing tens of thousands each. Control rates below 50% in most countries mean the return is largely unclaimed.
- 05
Smoking-cessation services
GRADE AEstablishedAmong the most cost-effective clinical interventions evaluatedBehavioural support plus pharmacotherapy, cost per QALY far below any conventional threshold, with years of life gained per quit even late in life. Pharmacy-delivered services extend reach cheaply.
- 06
Falls-prevention exercise programmes
GRADE BPromisingTrial-proven, cost-effective, unfundedPhysiotherapist-led balance and strength programmes: 23% fewer falls across 108 RCTs, cost-effective against hip-fracture costs, and delivered to a small fraction of the eligible population. The cheapest unexploited return in ageing policy; fall deaths rose while the evidence sat unused.
- 07
Organised cancer screening within guideline ages
GRADE BPromisingCost-effective inside the guidelines; negative outsideColorectal, cervical and breast screening programmes with call-recall are cost-effective within recommended ages and intervals; extending them to younger or lower-risk groups, or adding whole-body imaging, turns the return negative through false positives and overdiagnosis. Lung CT for heavy smokers is cost-effective; for everyone else it is not.
- 08
Active-travel and clean-air infrastructure
GRADE BPromisingHigh modelled returns; observational evidence; long paybackCycling and walking infrastructure, low-emission zones, parks. Health-economic models (WHO HEAT and similar) show strong benefit-cost ratios from physical activity and reduced pollution; the evidence is observational and quasi-experimental, and the payback is measured in decades rather than budget cycles.
- 09
Longevity clinics, national longevity institutes, epigenetic-age programmes
GRADE DInsufficient or unsafeNo demonstrated healthy-year returnPublic funding of longevity clinics, biological-age testing programmes and flagship institutes has no evidence of adding healthy years to a population and diverts budget from rows with evidence. Research funding is worth having for what it may discover; it is not an ROI line.
Why the ROI figures vary so much, and what a treasury should expect
Sources of variation in prevention ROI, and the honest reading
| Factor | Effect on the quoted ROI | Honest reading |
|---|---|---|
| Perspective (health budget vs societal) | Societal ROI includes productivity and welfare; budget ROI does not | Ask which budget receives the return |
| Discount rate (0–10% in the literature) | Low rates inflate long-horizon returns dramatically | Standardise; 3–3.5% is conventional |
| Publication bias | Positive evaluations are published more | Discount headline medians such as 14.3:1 |
| Longer life, higher lifetime cost | Prevention increases lifetime medical spending (van Baal 2008) | Cost-effective, not cost-saving |
| Time horizon | Taxation pays now; active travel pays in decades | Match instruments to horizons |
| Delivery and uptake | Modelled ROI assumes coverage; real coverage is lower, especially in deprived areas | Fund the delivery, not the model |
| Displacement | Savings in one budget appear as costs in another (pensions, social care) | Whole-of-government accounting |
Frequently asked questions
Which public longevity infrastructure solutions offer the best ROI?
Ranked on cost per healthy life-year: tobacco and alcohol taxation (cash-positive immediately); salt, sugar and trans-fat policy; adult vaccination delivery; hypertension detection and control; smoking-cessation services; falls-prevention exercise programmes; organised cancer screening within guideline ages; active-travel and clean-air infrastructure; and last, with no demonstrated return, longevity clinics and national longevity institutes.
Is prevention really a 14:1 return?
The 14.3:1 figure is a median across published evaluations (Masters et al. 2017), and the same authors flag publication bias, inconsistent methods and discount rates from 0% to 10%. Returns to the budget that pays are far lower than societal returns, and prevention increases lifetime medical costs because people live longer. Cost-effective is the defensible claim; 14:1 to a treasury is not.
Which prevention measures actually save money?
Tobacco and alcohol taxation, which raises revenue while reducing harm; most salt, sugar and trans-fat policies in models; and some adult vaccination programmes in some analyses. Almost everything else is cost-effective — worth the money per healthy year — rather than cost-saving, and should be funded on that basis.
Why does falls-prevention exercise rank as an unexploited return?
Because it has high-certainty trial evidence (23% fewer falls across 108 randomised trials), is cost-effective against the cost of hip fractures and care-home admission, and reaches a small fraction of eligible older adults. Fall deaths in the US rose 21% between 2018 and 2024, after the evidence was published. The return exists; the delivery does not.
Does more screening improve ROI?
No. Organised colorectal, cervical and breast screening are cost-effective within recommended ages and intervals; extending them to younger or lower-risk groups, shortening intervals, or adding whole-body imaging and multi-cancer blood tests outside trials turns the return negative through false positives, overdiagnosis and cascade costs. Lung CT is cost-effective only for heavy smokers.
Should governments fund longevity clinics or institutes for ROI?
Not as infrastructure ROI. Longevity clinics, biological-age programmes and flagship institutes have no evidence of adding healthy years at population scale, and public money spent on them is money not spent on rows with evidence. Research funding is justified by what it may discover, which is a different argument from return on investment.
Keep reading
- Public health and policy
The prevention economics with the caveats.
- How can governments fund public longevity infrastructure effectively?
The funding mechanisms ranked.
- Cost effective public longevity infrastructure solutions for healthy aging.
The same list from the cost side.
- Free stack check
Pharmacy delivery of the high-return rows.
More in Public health & policy
- What is public longevity infrastructure and why it matters?
Public longevity infrastructure defined — the laws, budgets, services and built environment a government uses to extend healthy life — and its components ranked by evidence: tobacco and alcohol policy, vaccination and screening delivery, hypertension control, primary and pharmacy care, air quality and active-travel design, falls prevention, and longevity research — with why the morbidity gap makes it matter now.
- How to invest in public longevity infrastructure projects?
How private capital can invest in public longevity infrastructure, ranked by instrument and project type: municipal and sovereign health bonds, social and health impact bonds, public-private partnerships for primary-care and diagnostic facilities, listed healthcare-infrastructure and REIT exposure, and impact funds — with what returns are realistic, what 'longevity dividend' figures actually mean, and the questions to ask before committing.
- How can governments fund public longevity infrastructure effectively?
Funding mechanisms for public longevity infrastructure ranked on whether money reaches delivery and survives budget cycles: earmarked health taxes, legally reserved prevention shares (EU4Health's 20%), ring-fenced prevention budgets, outcome-linked payments, general taxation with performance frameworks, and one-off capital programmes — with the evidence from the EU, UK and Singapore on what holds and what evaporates.
- What public longevity infrastructure strategies improve population health outcomes?
Public longevity strategies ranked on recorded population-health outcomes: fiscal and regulatory control of tobacco, alcohol and diet; universal primary care with enrolment (Singapore's Healthier SG model); organised vaccination and screening with call-recall; hypertension control at scale; deprivation-targeted delivery to close the 20-year healthy-life gap; healthy-ageing services; and target-led strategies without delivery — with what each has actually changed.
- How to evaluate impact of public longevity infrastructure?
A ranked method for evaluating public longevity infrastructure: pick outcomes that matter (healthy life expectancy by deprivation, morbidity gap), use designs that can attribute (randomised rollouts, stepped-wedge, difference-in-differences, synthetic controls), track delivery and coverage first, measure equity, model cost-effectiveness honestly, and avoid the evaluation traps that let target-led strategies claim success.
- What public longevity infrastructure models attract private investors?
Public longevity infrastructure models ranked on attracting private capital without distorting the health objective: availability-payment PPPs for primary-care and diagnostic facilities, earmarked-revenue bonds, outcome-based contracts and impact bonds, blended-finance funds with public first-loss capital, and concession models for healthy-ageing services — with what investors actually need, what governments must protect, and the models that go wrong.